PE Deals Syncona to buy Freeline Therapeutics Freeline is a clinical-stage biotechnology company. Irien Joseph - 22 November 2023 Share A- A+ 100% Create an account to continue reading Gain instant access to our expert editorial analysis and in-depth insight. Register for free Already have an account? Sign in
